M. Jansen

发表

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

C. Takimoto, S. Mani, M. Mita, 2009, Clinical Cancer Research.

Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820

J. Wanders, J. Schellens, J. Beijnen, 2009, Investigational New Drugs.

Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog.

T. Abribat, I. Darby, J. Hardy, 2004, International journal of pharmaceutics.

Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types

B. Hendriks, N. Terranova, M. Jansen, 2020, Cancer Chemotherapy and Pharmacology.

Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.

A. Scott, M. Brechbiel, G. O'Keefe, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

(403) Co-administration of mirogabalin and zolpidem in healthy subjects: results from a randomized, double-blind, drug-drug interaction study.

H. Zahir, D. Merante, K. Brown, 2016, The journal of pain : official journal of the American Pain Society.

A Randomized, Placebo‐Controlled, Double‐Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers

K. Brown, S. Warrington, V. Dishy, 2018, Clinical pharmacology in drug development.

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

Mats O. Karlsson, Jos H. Beijnen, Ron J. Keizer, 2010, Journal of Pharmacokinetics and Pharmacodynamics.

Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors

J. Mendell, Shuquan Chen, N. Matsushima, 2016, Cancer Chemotherapy and Pharmacology.

First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors

P. LoRusso, J. Bendell, G. Senaldi, 2018, Investigational New Drugs.

453 Population pharmacokinetics (PK) and exposure/response relationships of the receptor tyrosine kinase inhibitor E7080 in phase I studies

J. Wanders, W. Hanekom, Anubha Gupta, 2010 .

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug‐Drug Interaction Studies in Healthy Subjects

H. Zahir, J. Mendell, Ling He, 2018, Clinical pharmacology in drug development.

Exposure-Response Relationship to Assess the Risk of Neutropenia in Patients With Hepatocellular Carcinoma (HCC) Treated With Tivantinib

Raymond Miller, G. Abbadessa, H. Kastrissios, 2012 .